92 related articles for article (PubMed ID: 11223350)
1. The role and clinical applications of bioactive lysolipids in ovarian cancer.
Xu Y; Xiao YJ; Baudhuin LM; Schwartz BM
J Soc Gynecol Investig; 2001; 8(1):1-13. PubMed ID: 11223350
[TBL] [Abstract][Full Text] [Related]
2. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells.
Schwartz BM; Hong G; Morrison BH; Wu W; Baudhuin LM; Xiao YJ; Mok SC; Xu Y
Gynecol Oncol; 2001 May; 81(2):291-300. PubMed ID: 11330965
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
[TBL] [Abstract][Full Text] [Related]
4. Lysophospholipids are potential biomarkers of ovarian cancer.
Sutphen R; Xu Y; Wilbanks GD; Fiorica J; Grendys EC; LaPolla JP; Arango H; Hoffman MS; Martino M; Wakeley K; Griffin D; Blanco RW; Cantor AB; Xiao YJ; Krischer JP
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1185-91. PubMed ID: 15247129
[TBL] [Abstract][Full Text] [Related]
5. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
Tanyi JL; Morris AJ; Wolf JK; Fang X; Hasegawa Y; Lapushin R; Auersperg N; Sigal YJ; Newman RA; Felix EA; Atkinson EN; Mills GB
Cancer Res; 2003 Mar; 63(5):1073-82. PubMed ID: 12615725
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis.
Murph M; Tanaka T; Pang J; Felix E; Liu S; Trost R; Godwin AK; Newman R; Mills G
Methods Enzymol; 2007; 433():1-25. PubMed ID: 17954226
[TBL] [Abstract][Full Text] [Related]
7. Unfolding the pathophysiological role of bioactive lysophospholipids.
Xu Y; Xiao YJ; Zhu K; Baudhuin LM; Lu J; Hong G; Kim KS; Cristina KL; Song L; S Williams F; Elson P; Markman M; Belinson J
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Mar; 3(1):23-32. PubMed ID: 12570723
[TBL] [Abstract][Full Text] [Related]
8. The G protein-coupled receptor GPR4 suppresses ERK activation in a ligand-independent manner.
Bektas M; Barak LS; Jolly PS; Liu H; Lynch KR; Lacana E; Suhr KB; Milstien S; Spiegel S
Biochemistry; 2003 Oct; 42(42):12181-91. PubMed ID: 14567679
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid production and action: validated targets in cancer?
Umezu-Goto M; Tanyi J; Lahad J; Liu S; Yu S; Lapushin R; Hasegawa Y; Lu Y; Trost R; Bevers T; Jonasch E; Aldape K; Liu J; James RD; Ferguson CG; Xu Y; Prestwich GD; Mills GB
J Cell Biochem; 2004 Aug; 92(6):1115-40. PubMed ID: 15258897
[TBL] [Abstract][Full Text] [Related]
10. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids.
Xiao YJ; Schwartz B; Washington M; Kennedy A; Webster K; Belinson J; Xu Y
Anal Biochem; 2001 Mar; 290(2):302-13. PubMed ID: 11237333
[TBL] [Abstract][Full Text] [Related]
11. Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.
Baba T; Mori S; Matsumura N; Kariya M; Murphy SK; Kondoh E; Kusakari T; Kuroda H; Mandai M; Higuchi T; Takakura K; Fukuda MN; Fujii S
Biochem Biophys Res Commun; 2007 Aug; 360(2):363-9. PubMed ID: 17597582
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
13. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
[TBL] [Abstract][Full Text] [Related]
14. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
15. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.
Connor JP; Felder M
Gynecol Oncol; 2008 Nov; 111(2):330-5. PubMed ID: 18723214
[TBL] [Abstract][Full Text] [Related]
16. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
17. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of the endothelin axis in ovarian tumor progression.
Bagnato A; Spinella F; Rosanò L
Endocr Relat Cancer; 2005 Dec; 12(4):761-72. PubMed ID: 16322321
[TBL] [Abstract][Full Text] [Related]
19. Migration of vascular smooth muscle cells induced by sphingosine 1-phosphate and related lipids: potential role in the angiogenic response.
Boguslawski G; Grogg JR; Welch Z; Ciechanowicz S; Sliva D; Kovala AT; McGlynn P; Brindley DN; Rhoades RA; English D
Exp Cell Res; 2002 Apr; 274(2):264-74. PubMed ID: 11900487
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
